Eluvia banner image

The New Standard of Care for Long Complex Lesions

Eluvia Drug-Eluting Stent

Proven Superiority. Longest PTX Drug- Eluting Stent

EluviaTM is the unrivaled SFA stent. 

EluviaTM Drug-Eluting Stent (DES) was designed to address the peak of restenosis1, providing continuous release of paclitaxel for up to 12 months, unlike other drug-eluting stents which only release it for 2-3 months, ensuring ongoing protection during the critical period.​

Clinical history of restenosis

Eluvia™ Drug Eluting Stent (DES) is the only commercially available DES to have been tested – and proven superior – in three separate head-to-head randomised controlled trials.

Icon representing positive result

Proven superiority
to BMS AND Zilver PTX in RCTs


Consistent performance
for all your patients
~90% Patency at 1 year

Icon representing reduction

Lowest TLR rate
of any SFA stent
~9/10 TLR-free at 2 years

Proven superiority

In the unmatched performance levels of the Eluvia™ Drug Eluting Stent (DES), we have invested prospective randomised controlled head-to-head trials against competitive technologies. ​

The EMINENT2, IMPERIAL3, and SPORTS4 Trials each met their primary endpoint and provide you with level-1 evidence of Eluvia’s superior primary patency versus BMS and Zilver PTX, respectively.​


We invested in 2 randomised controlled trials  that demonstrated Eluvia's superiority over both BMS and Zilver PTX.​

More Confidence with Level-1 RCTs

SUPERIOR to both BMS and Zilver PTX in RCTs

Eluvia’s superior primary patency.

Eluvia’s 1-year drug elution delivers statistically superior outcomes to BMS and DCB. ​

Eluvia’superior outcomes to BMS and DCB

Consistency performance

The evidence of Eluvia’s superior primary patency is not limited to the controlled setting of RCTs – in study after study, real-world evidence confirms consistently high (90%) primary patency rates in patients that reflect  the real-world challenges you face in treating PAD in the SFA– long lesions, complex lesions and patients with compromising comorbidities2-12​

More Evidence in real world patients

Consistent performance for all your patients.

Eluvia's consistent performance.
Eluvia's consistent performance.png
148 KB
Download this graph

Lowest TLR rate of any SFA stent at 2 years

Studies supporting Eluvia’s superiority extend beyond primary patency and one-year follow-up to show durable outcomes.  When you choose Eluvia to treat PAD in the SFA – even in patients with complex lesions or comorbidities – it’s an evidence-based decision, with studies showing that 9 out of 10 patients are TLR-free after two years.2-12 ​

More Successful Outcomes for your patients

Lowest TLR rate of any SFA stent at 2 years.

Eluvia's lowest TLR rate
Eluvia TLR rate.png
133 KB
Download this graph


  1. Iida O, Uematsu M, Soga Y, et al. Timing of the restenosis following nitinol stenting in the superficial femoral artery and the factors associated with early and late restenosis. Catheter Cardiovasc Interv. 2011;78(4):611–617.​

  2. Imperial: Gray WA, Keirse K, Soga Y, et al; IMPERIAL investigators. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. Lancet. 2018;27;392(10157):1541–1551. Müller-Hülsbeck S, Benko A, Soga Y, et al. Two-year efficacy and safety results from the IMPERIAL Randomized study of the Eluvia polymer-coated drug-eluting stent and the Zilver PTX polymer-free drug-coated stent. Cardiovasc Intervent Radiol. 2021;44:368–375.​

  3. EMINENT: Gouëffic Y, et al. Efficacy of a drug-eluting stent versus bare metal stents for symptomatic femoropopliteal peripheral artery disease: Primary results of the EMINENT randomized trial. Circulation. 2022;146:1564–1576.​

  4. SPORTS: Tepe G. SPORTS. TCT 2023, October 24, 2023, San Francisco, CA.​

  5. Majestic: Müller-Hülsbeck S, Charing Cross 2015. Müller-HülsbeckS, et al. Cardiovasc Intervent Radiol. 2017;40(12):1832-1838.​

  6. Regal: Lansik W. Real world all comers data from the REGAL registry – 2-year results. Presented at LINC 2023.​

  7. Auckland: Holden, A. Single Centre Long-Term Experience with the Boston Scientific Eluvia DES in Femoro-popliteal Artery Occlusive Disease. LINC 2020.​

  8. IMPERIAL Long: Müller-Hülsbeck S, et al. Two-year efficacy and safety results from the IMPERIAL Randomized study of the Eluvia polymer-coated drug-eluting stent and the Zilver PTX polymer-free drug-coated stent. Cardiovasc Intervent Radiol. 2021;44:368–375.​

  9. Capsicum: Iida O, Takahara M, Soga Y, et al; CAPSICUM Investigators. 1-Year Outcomes of Fluoropolymer-Based Drug-Eluting Stent in Femoropopliteal Practice: Predictors of Restenosis and Aneurysmal Degeneration. JACC Cardiovasc Interv. 2022 Mar 28;15(6):630–638. Iida LINC 2023.​

  10. Desafinado: Kum S, Ipema J, Huizing E, et al. Outcomes of the paclitaxel-eluting Eluvia stent for long femoropopliteal lesions in Asian patients with predominantly chronic limb-threatening ischemia. Vasc Med. 2021;26(3):267–272.​

  11. Muenster: Stavroulakis K, Torsello G, Bosiers M. 2-Year Outcomes of the Eluvia Drug-Eluting Stent for the Treatment of Complex Femoropopliteal Lesions. JACC Cardiovasc Interv. 2021;14(6):692–701.​

  12. Ultimate: Ichihashi S, Takahara M, Yamaoka T, et al. Drug eluting versus covered stent for femoropopliteal artery lesions: Results of the ultimate study. Eur J Vasc Endovasc Surg. 2022;64(4);359–366.​

The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.